绥美凯医保价格

On January 22, 2018, GlaxoSmithKline (GSK) announced that its controlled joint venture ViiV Healthcare’s new-generation integrase inhibitor for the treatment of HIV was officially launched in mainland China. This drug is the only three-in-one compound drug containing dolutegravir. It is a once-daily, one-tablet drug. It has the characteristics of high efficacy, good tolerance, high resistance barrier, and few drug interactions. 

Suimeikai is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China.

It is understood that the domestic price of Suimeikan (alias: Domitabalamid Tablets) is 2,880$/box. So what is the price of Suimeikan medical insurance?

According to Medical Companion Travel, Suimeikai has not been included in the medical insurance since it was launched in China not long ago, and it is a self-pay drug for patients. Since Suimeikai is an imported original drug in China, it is very expensive and most patients cannot afford it. Therefore, many patients choose Suimeikai, which is launched in India.

Suimeikai, produced by the Indian company Emcure, comes in a box of 30 tablets and sells for about RMB 1,000. The price cannot be determined due to the floating exchange rate. Please consult Medical Travel for the specific price.

In addition, patients treated with Suimeikan cannot be used on individuals who carry the HLA-B*5701 gene. Patients carrying this gene will have a high risk of severe hypersensitivity reactions (type I allergic reactions) when using Suimeikan.

Therefore, before taking Suimeikai, you need to complete the test to determine whether you carry the special type of "HLA-B*5701" gene.

The launch of the drug will significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and significantly improving their quality of life.

Recommended related hot articles: /newsDetail/71968.html